AI co-scientist: a multi-agent system for generating hypotheses
A system based on Gemini 2.0 that generates hypotheses and research proposals. In the lab, three drugs it suggested for repurposing against acute myeloid leukemia reduced cancer-cell viability, and all suggested treatments for liver fibrosis showed activity. Expert assessments covered only 11 targets; fibrosis results awaited a Stanford report.
Technology: AI co-scientist (Gemini 2.0, multi-agent)
Family AI Co-Scientist: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Elo auto-evaluation over 203 research goals; 15 expert-curated goals; blinded experts rated 11 goals (preference rank 2.36). In vitro on four AML cell lines: binimetinib, pacritinib, cerivastatin reduced viability; KIRA6 IC50 10 nM in KG-1a versus 180 nM in TK6. Seven combinations tested.
- Still unknown: The paper calls validation preliminary and in vitro only. KIRA6 was far less effective in MOLM-13 and HL-60. Expert evaluation was small and subjective; Elo is not ground truth. Liver fibrosis and AMR details are summarized only.
- AI role: A Gemini-based multi-agent system generated, debated and ranked hypotheses; experts selected candidates and prioritized lab experiments.
Evidence sources: https://doi.org/10.1038/s41586-026-10644-y
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.